John Libbey Eurotext

European Journal of Dermatology


Effect of a novel “emollient plus” formulation on mild-to-severe atopic dermatitis and other dry skin-related diseases as monotherapy or adjunctive therapy: an observational study on efficacy, tolerance and quality of life in adult patients Volume 33, issue 2, March-April 2023


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

  • Figure 5

  • Figure 6

  • Figure 7

  • Figure 8

  • Figure 9

  • Figure 10

  • Figure 11

  • Figure 12

  • Figure 13


1 Autoimmune Skin and Bullous Diseases Outpatient Unit of Papageorgiou General Hospital, 2nd Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, 541 24, Greece
2 First Department of Dermatology-Venereology, Aristotle University, State Hospital of Skin and Venereal Diseases, Thessaloniki, 541 24, Greece
3 Second Department of Dermatology-Venereology, Attikon University Hospital, Hospital of Skin and Venereal Diseases, Athens, 124 62, Greece
4 Department of Dermatology, University of Athens, Andreas Sygros Hospital, 161 21, Athens, Greece
5 Private Clinic, Argolidos 2, 115 23, Athens, Greece
6 Department of Dermatology, School of Medicine, University of Patras, Rio-Patras, 265 04, Greece
* Reprints: Pasmatzi Efstathia
* These authors contributed equally

Background: Atopic dermatitis (AD), psoriasis and senile xerosis comprise common chronic and relapsing inflammatory skin disorders with clinical symptoms such as lichenification, pruritus and inflammatory lesions that affect the quality of life of patients. Objectives: In this study, we aimed to evaluate the efficacy of a novel “emollient plus” formulation (Lipikar baume AP+M), containing non-living lysates of non-pathogenic Vitreoscilla Filiformis bacteria from LaRoche-Posay Thermal Spring water, in improving quality of life, alleviating skin pain, and managing symptoms of mild-to-severe AD or skin disorders associated with dryness or severe xerosis in adults. Materials & Methods: The study included 1,399 adult patients, who participated in a two-month observational study over two visits, conducted at dermatologists’ practices. Visits included clinical assessment of skin disease before and after administration of the product as well as completion of the 10-question Dermatology Life Quality Index. Questionnaires were used to evaluate efficacy, safety, satisfaction and tolerance of the product both by the dermatologists and patients, as well as assess quality of life of patients. Results: Statistically significant improvement (p<0.001) by at least one grade was observed by more than 90% based on patients’ evaluation of efficacy regarding intensity of the skin disease, skin dryness, surface affected by inflammatory lesions, pruritus, quality of sleep, daily discomfort, dryness and desquamation. Quality of life after two months improved by 82.6%. Conclusion: This study demonstrated significant reduction in symptoms of mild-to-severe skin dryness after application of the “emollient plus” formulation over two months, either alone or as adjunctive therapy.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License